1033625-15-8

Basic information

• Product Name: di-tert-butyl (4-(2,2,5,5-tetramethylborolan-1-yl)-1,2-phenylene)dicarbamate
• Synonyms: di-tert-butyl (4-(2,2,5,5-tetramethylborolan-1-yl)-1,2-phenylene)dicarbamate
• CAS NO: 1033625-15-8
• Molecular Weight: 434.341
• Mol File: 1033625-15-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: di-tert-butyl (4-(2,2,5,5-tetramethylborolan-1-yl)-1,2-phenylene)dicarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: di-tert-butyl (4-(2,2,5,5-tetramethylborolan-1-yl)-1,2-phenylene)dicarbamate(1033625-15-8)
• EPA Substance Registry System: di-tert-butyl (4-(2,2,5,5-tetramethylborolan-1-yl)-1,2-phenylene)dicarbamate(1033625-15-8)

Safety Data

• Hazardous Substances Data: 1033625-15-8(Hazardous Substances Data)

Upstream product

• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 471239-60-8 di-tert-butyl (4-bromobenzene-1,2-diyl)biscarbamate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1296796-59-2 tetrakis(1,1-dimethylethyl) (2,5-pyridinediyldibenzene-4,1,2-triyl)tetrakiscarbamate 
• 1296797-03-9 bis(1,1-dimethylethyl)(3,4-diamino-1,1':4',1-terphenyl-3,4-diyl)biscarbamate 
• 1296797-40-4 bis(1,1-dimethylethyl)(4'-bromo-3,4-biphenyldiyl)biscarbamate 
• 1296797-04-0 methyl [(1S)-1-({(8S)-8-[5-(3',4'-diamino-4-biphenylyl)-1H-benzimidazol-2-yl]-1,4-dioxa-7-azaspiro[4.4]non-7-yl}carbonyl)-2-methylpropyl]carbamate 
• 1296797-44-8 bis(1,1-dimethylethyl)bis(phenylmethyl)1,1':4',1-terphenyl-3,3,4,4-tetrayltetrakiscarbamate 
• 1415120-56-7 C₄₈H₆₀N₄O₈ 

Relevant articles and documents

Synthesis and Reactivity of 18F-Labeled α,α-Difluoro-α-(aryloxy)acetic Acids

In this work, we describe the 18F-labeling of α,α-difluoro-α-(aryloxy)acetic acid derivatives and demonstrate that these building blocks are amenable to post-18F-fluorination functionalization. Protodecarboxylation offers a new entry to 18F-difluoromethoxyarene, and the value of this approach is further demonstrated with coupling processes leading to representative 18F-labeled TRPV1 inhibitors and TRPV1 antagonists.

CHEMICAL COMPOUNDS

Disclosed are compounds of Formula (I). Also disclosed are pharmaceutical compositions comprising the compounds, and methods for treating HCV invention by administration of the compounds.